APA (7th ed.) Citation

Lendvai, N., Tsakos, I., Devlin, S. M., Schaffer, W. L., Hassoun, H., Lesokhin, A. M., . . . Landgren, O. (2018). Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leukemia & lymphoma, 59(8), 1981-1985. https://doi.org/10.1080/10428194.2017.1403020

Chicago Style (17th ed.) Citation

Lendvai, Nikoletta, et al. "Predictive Biomarkers and Practical Considerations in the Management of Carfilzomib-associated Cardiotoxicity." Leukemia & Lymphoma 59, no. 8 (2018): 1981-1985. https://doi.org/10.1080/10428194.2017.1403020.

MLA (9th ed.) Citation

Lendvai, Nikoletta, et al. "Predictive Biomarkers and Practical Considerations in the Management of Carfilzomib-associated Cardiotoxicity." Leukemia & Lymphoma, vol. 59, no. 8, 2018, pp. 1981-1985, https://doi.org/10.1080/10428194.2017.1403020.